Comparison of the efficacy and safety of sertraline, reboxetine, and venlafaxine in patients with major depressive disorder: A pooled analysis of four randomized, open-label trials

Klinik Psikofarmakoloji Bulteni

Volumn 20, Issue 4, 2010, Pages 274-287

  Akkaya, Cengiz ^a   Kirli, Selcuk ^a   Eker, Salih Saygin ^a   Cangur, Sengul ^a   Canbazoglu, Mustafa ^a   Sarandol, Asli ^a  

^a ULUDAG UNIVERSITY   (Turkey)

Author keywords

Antidepressant; Neurotransmitters; Reboxetine; Sertraline; Unipolar depression; Venlafaxine

Indexed keywords

REBOXETINE; SERTRALINE; VENLAFAXINE;

ADULT; AGED; ARTICLE; CONSTIPATION; DEMOGRAPHY; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; FLUSHING; HAMILTON SCALE; HEADACHE; HOT FLUSH; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; NAUSEA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOCIAL ASPECT; SWEATING; TACHYCARDIA; VERTIGO; XEROSTOMIA;

EID: 79251529523     PISSN: 10177833     EISSN: 13029657     Source Type: Journal    
DOI: 10.1080/10177833.2010.11790673     Document Type: Article

References (71)

1. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen HU, Kendler KS. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51:8-19.
2. Langworth S, Bodlund O, Agren H. Efficacy and tolerability of reboxetine compared with citalopram: a double-blind study in patients with major depressive disorder. J Clin Psychopharmacol 2006; 26:121-7. (Pubitemid 43740334)
3. Belmaker RH, Agam G. Major depressive disorder. N Eng J Med 2008; 358: 55-68.
4. Cusack B, Nelson A, Richelson E. Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology 1994; 114:559-565. (Pubitemid 24152135)
5. Frazer A. Antidepressants. J Clin Psychiatry 1997; 58:9-25.
6. Kasper S, Praschak-Rieder N, Tauscher J, Wolf R. A risk-benefit assessment of mirtazapine in the treatment of depression. Drug Saf 1997; 17:251-264. (Pubitemid 27466515)
7. Brunello N, Mendlewicz J, Kasper S, Leonard B, Montgomery S, Nelson J, Paykel E, Versiani M, Racagni G. The role of noradrenaline and selective noradrenaline reuptake inhibition in depression. Eur Neuropsychopharmacol 2002; 12:461-475.
8. Healy D, McMonagle T. The enhancement of social functioning as a therapeutic principle in the management of depression. J Psychopharmacol 1997; 11:25-31.
9. Montgomery SA. Reboxetine: additional benefits to the depressed patient. J Psychopharmacol 1997; 11:9-15.
10. Montgomery SA, Fineberg N. Is there a relationship between serotonin receptor subtypes and selectivity of response in specific psychiatric illnesses? Br J Psychiatry 1989; 8: 63-69.
11. Ayuso- Gutiérrez JL. Depressive subtypes and efficacy of antidepressive pharmacotherapy. World J Biol Psychiatry 2005; 6: 31-37.
12. Naito S, Sato K, Yoshida K, Higuchi H, Takahashi H, Kamata M, Ito K, Ohkubo T, Shimizu T. Gender differences in the clinical effects of fluvoxamine and milnacipran in Japanese major depressive patients. Psychiatry Clin Neurosci 2007; 61: 421-427.
13. Eker SS, KirliS Akkaya C, Cangür S, Sarandöl A. Are there differences between serotonergic, noradrenergic and dual acting antidepressants in the treatment of depressed women? World J Biol Psychiatry 2009; 10:400-408.
14. Coleman CC, Cunningham LA, Foster VJ, Batey SR, Donahue RM, Houser TL, Ascher JA. Sexual dysfunction associated with the treatment of depression: a placebo-controlled comparison of bupropion sustained release and sertraline treatment. Ann Clin Psychiatry 1999; 11:205-215.
15. Croft H, Settle E, Jr Houser T, Batey SR, Donahue RM, Ascher JA. A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline. Clin Ther 1999; 21:643-658.
16. M Coskun, S Zoroglu. Clozapine induced obsessions treated with sertraline in an adolescent with schizophrenia. Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology 2009; 19:155-158.
17. A Doruk, S Yetkin, H Aydin. The efficacy of sertraline on posttraumatic stress disorder Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology 1999; 9:47-52.
18. R Askin, M Turan, AS Cilli, N Kaya. Clomipramine versus sertraline in the treatment of obsessive compulsive disorder. Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology 1999; 9:133-138.
19. MZ Saygin, MZ Sungur, EU Sabol, P Cetinkaya. Nefazodone versus sertraline in the treatment of posttraumatic stress disorder. Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology 2002; 12:1-5.
20. C Celik, M Erdem, B Ozdemir, T Cayci, T Turker, F Ozgen. Treatment of major depression with sertraline: Relationship between serum neopterin levels and respond to the treatment. Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology 2010; 20:139-144.
21. Hajós M, Fleishaker JC, Filipiak-Reisner JK, Brown MT, Wong EH. The Selective Norepinephrine Reuptake Inhibitor Antidepressant Reboxetine: Pharmacological and Clinical Profile. CNS Drug Rev 2004; 10: 23-44.
22. Papakostas GI, Nelson JC, Kasper S, Moller HJ. A meta-analysis of clinical trials comparing reboxetine, a norepinephrine reuptake inhibitor, with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. Eur Neuropsychopharmacol 2008; 18:122-127.
23. Papakostas GI, Thase ME, Fava M, Nelson JC, Shelton RC. Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biol Psychiatry 2007; 62:1217-1227.
24. Eker SS, Akkaya C, Akgoz S, Sarandol A, Kirli S. Comparison of Reboxetine and Sertraline in Terms of Efficacy and Safety in Major Depressive Disorder (Majör Depresif Bozuklukta Sertralin ve Reboksetin'in Etkinlik ve Güvenilirliǧinin Karşilaştirilmasi). Türk Psikiyatri Dergisi 2005; 16:153-163.
25. Massana J, Moller HJ, Burrows GD, Montenegro RM. Reboxetine: a double-blind comparison with fluoxetine in major depressive disorder. Int Clin Psychopharmacol 1999; 14:73-80.
26. Stahl SM, Entsuah R, Rudolph RL. Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression. Biol Psychiatry 2002; 52:1166-1174.
27. Mehtonen OP, Sogaard J, Roponen P, Behnke K. Randomized, double-blind comparison of venlafaxine and sertraline in outpatients with major depressive disorder. Venlafaxine 631 Study Group. J Clin Psychiatry 2000; 61:95-100. (Pubitemid 30141641)
28. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001; 178:234-241. (Pubitemid 32183606)
29. Smith D, Dempster C, Glanville J, Freemantle N, Anderson I. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br J Psychiatry 2002; 180:396-404. (Pubitemid 34499333)
30. Schmitt AB, Bauer M, Volz HP, Moeller HJ, Jiang Q, Ninan PT, Loeschmann PA. Differential effects of venlafaxine in the treatment of major depressive disorder according to baseline severity. Eur Arch Psychiatry Clin Neurosci 2009; 259:329-339.
31. Shelton RC, Haman KL, Rapaport MH, Kiev A, Smith WT, Hirschfeld RM, Lydiard RB, Zajecka JM, Dunner DL. A randomized, double-blind, active-control study of sertraline versus venlafaxine XR in major depressive disorder. J Clin Psychiatry 2006; 67:1674-1681. (Pubitemid 44955146)
32. Sir A, D'Souza RF, Uguz S, George T, Vahip S, Hopwood M, Martin AJ, Lam W, Burt T. Randomized trial of sertraline versus venlafaxine XR in major depression: efficacy and discontinuation symptoms. J Clin Psychiatry 2005 66:1312-1320. (Pubitemid 41546512)
33. Papakostas GI. Major depressive disorder: similar remission rates with bupropion, sertraline, or venlafaxine following treatment switch from citalopram. Evid Based Ment Health 2006; 9:100.
34. Dursun SM, Devarajan S. Reboxetine plus citalopram for refractory depression not responding to venlafaxine: possible mechanisms. Psychopharmacology (Berl) 2001; 153:497-498. (Pubitemid 32202070)
35. Lopez-Munoz F, Alamo C, Rubio G, Garcia-Garcia P, Pardo A. Reboxetine combination in treatment-resistant depression to selective serotonin reuptake inhibitors. Pharmacopsychiatry 2007; 40:14-19. (Pubitemid 46568355)
36. Akkaya C, Sivrioglu EY, Sarandol A, Kirli S. Major depresif bozuklukta venlafaxine XR ve reboksetin'in etkinlik ve guvenilirliginin karsilastirilmasi (Comparison of venlafaxine XR and reboxetine in terms of efficacy and safety in major depressive disorder). Yeni Symposium 2003; 41:170-177.
37. Yazicioglu B, Akkaya C, Sarandol A, Akgoz S, Salih Saygin E, Kirli S. A comparison of the efficacy and tolerability of reboxetine and sertraline versus venlafaxine in major depressive disorder: a randomized, open-labeled clinical trial. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30:1271-1276. (Pubitemid 44216069)
38. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 2000.
39. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23:56-62.
40. Akdemir A, Turkcapar MH, Orsel SD, Demirergi N, Dag I, Ozbay MH. Reliability and validity of the Turkish version of the Hamilton Depression Rating Scale. Compr Psychiatry 2001; 42:161-165. (Pubitemid 32207252)
41. Bech P, Gram LF, Dein E, Jacobsen O, Vitger J, Bolwig TG. Quantitative rating of depressive states. Acta Psychiatr Scand 1975; 51:161-70.
42. Santen G, Gomeni R, Danhof M, Della Pasqua O. Sensitivity of the individual items of the Hamilton depression rating scale to response and its consequences for the assessment of efficacy. J Psychiatr Res 2008; 42:1000-1009.
43. Morse DT. Minsize2: a Computer Program for Determining Effect Size and Minimum Sample Size for Statistical Significance for Univariate, Multivariate, and Nonparametric Tests. Educational and Psychological Measurement 1999; 59: 518-531.
44. Siegel S, Castellan NJ. Nonparametric Statistics for the Behavioral Sciences. New York: McGraw-Hill, 1988.
45. Poirier MF, Boyer P. Venlafaxine and paroxetine in treatment-resistant depression: Double-blind, randomized comparison. Br J Psychiatry 1999; 175:12-16. (Pubitemid 29307849)
46. Luthringer R, Toussaint M, Schaltenbrand N, Bailey P, Danjou PH, Hackett D, Guichoux JY, Macher JP. A double-blind, placebo controlled evaluation of the effects of orally administered venlafaxine on sleep in inpatients with major depression. Psychopharmacol Bull 1996; 32:637-646. (Pubitemid 26428267)
47. Silverstone PH. Qualitative review of SNRIs in anxiety. J Clin Psychiatry 2004; 65:19-28.
48. Feighner JP. The role of venlafaxine in rational antidepressant therapy. J Clin Psychiatry 1994; 55:62-68.
49. Reimherr FW, Chouinard G, Cohn CK, Cole JO, Itil TM, LaPierre YD, Masco HL, Mendels J. Antidepressant efficacy of sertraline: a double-blind, placebo- and amitriptyline-controlled, multicenter comparison study in outpatients with major depression. J Clin Psychiatry 1990; 51:18-27.
50. Labbate LA, Grimes J, Hines A, Oleshansky MA, Arana GW. Sexual dysfunction induced by selective serotonin reuptake antidepressants. J Sex Marital Ther 1998; 24:3-12. (Pubitemid 28049559)
51. Montejo-González AL, Llorca G, Izquierdo JA, Ledesma A, Bousoño M, Calcedo A, Carrasco JL, Ciudad J, Daniel E, De la Gandara J, Derecho J, Franco M, Gomez MJ, Macias JA, Martin T, Perez V, Sanchez JM, Sanchez S, Vicens E. SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. J Sex Marital Ther 1997; 23:176-194.
52. Coplan JD, Gorman JM, Klein DF. Serotonin-related function in PD: a critical overview. Neuropsychopharmacol 1992; 6:189-200.
53. Gorman JM, Kent JM, Sullivan GM, Coplan JD. Neuroanatomical hypothesis of PD, revised. Am J Psychiatry 2000; 157:493-505.
54. Roy-Byrne PP, Cowley DS. Search for pathophysiology of PD. Lancet 1998; 352: 1646-1647.
55. Allgulander C, Dahl AA, Austin C, Morris PL, Sogaard JA, Fayyad R, Kutcher SP, Clary CM. Efficacy of sertraline in a 12-week trial for generalized anxiety disorder. Am J Psychiatry 2004; 161:1642-1649.
56. Brawman-Mintzer O, Knapp RG, Rynn M, Carter RE, Rickels K. Sertraline treatment for generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2006; 67:874-881.
57. Dubini A, Bosc M, Polin V. Noradrenaline-selective versus serotonin-selective antidepressant therapy: differential effects on social functioning. J Psychopharmacol 1997; 11:17-23.
58. Ban TA, Gaszner P, Aguglia E, Batista R, Castillo A, Lipcsey A. A comparative study with desipramine, with methodological considerations. Hum Psychopharmacol 1998; 13:29-39.
59. Versiani M, Amin M, Chouinard G. Double-blind, placebo-controlled study with reboxetine in inpatients with severe major depressive disorder. J Clin Psychopharmacol 2000; 20:28-34.
60. Ferguson JM, Mendels J, Schwartz GE. Effects of reboxetine on Hamilton Depression rating Scale factors from randomized, placebo-controlled trials in major depression. Int Clin Psychopharmacol 2002; 17:45-51.
61. Stahl SM. Essential Psychopharmacology. New York: Cambridge University Press, 2000.
62. Clerc GE, Ruimy P, Verdeau-Pailles J. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. Int Clin Psychopharmacol 1994; 9:139-143.
63. Hirschfeld RM. Efficacy of SSRIs and newer antidepressants in severe depression: comparison with TCAs. J Clin Psychiatry 1999; 60:326-335.
64. Lenox-Smith AJ, Jiang Q. Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor. Int Clin Psychopharmacol 2008; 23:113-119.
65. Nelson JC, Portera L, Leon AC. Residual symptoms in depressed patients after treatment with fluoxetine or reboxetine. J Clin Psychiatry 2005; 66:1409-1414.
66. Sivrioglu EY, Topaloglu VC, Sarandol A, Akkaya C, Eker SS, Kirli S. Reboxetine induced erectile dysfunction and spontaneous ejaculation during defecation and micturition. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:548-50.
67. Bertoli R, Girardin F, Russmann S, Lauterburg BH. Raynaud's phenomenon induced by drugs acting on neurotransmission: two cases under reboxetine and one under tegaserod. Eur J Clin Pharmacol 2003; 58:717.
68. FO Orhan, B Zencirci, H Oksuz, A Bayir, MF Karaaslan. Development of neuroleptic malignant syndrome after addition of sertraline to the treatment: A case report Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology 2007; 17:30-33.
69. O Uzun, A Cansever, F Ozgen Hair loss due to sertralin use: a case report Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology 2003; 13:27-29.
70. Lepine JP, Caillard V, Bisserbe JC, Troy S, Hotton JM, Boyer P. A randomized, placebo-controlled trial of sertraline for prophylactic treatment of highly recurrent major depressive disorder. Am J Psychiatry 2004; 161:836-842. (Pubitemid 38625336)
71. Schweizer E, Rynn M, Mandos LA, Demartinis N, Garcia-Espana F, Rickles K. The antidepressant effect of sertraline is not enhanced by dose titration: results from an outpatient clinical trial. Int Clin Psychopharmacol 2001; 16:137-43. (Pubitemid 32402358)